The DOI matches its Crossref record.
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Abstract
P erusal of advertisements for oral hy-poglycemic agents in this and manyother medical journals shows an emphasis on the absolute reduction in HbA1c (A1C). Evidence linking reduction in A1C in diabetic patients to prevention of macrovascular events is weak. How-ever, epidemiological evidence suggests that the risk for cardiovascular disease in this group may actually begin at A1C con-centrations well within the normal range (1). This association has led a number of professional organizations to recommend that A1C levels be brought to levels 6.5 % (2). An important question to be asked is whether the reduction in A1C differs at lower versus higher baseline lev-els of A1C. Expectations for the degree of reduction to be attained with a given agent may be excessively optimistic when a person’s initial A1C is already 7.5– 8.0%. Some of the deliberations of policy advisory groups are available. The Euro-pean Agency for the Evaluation of Medic-inal Products has published guidelines for diabetes product evaluation suggesting that the change in A1C be utilized as “pri-mary analysis ” of drug efficacy, although allowing the baseline A1C to be included as a covariate (3). A meeting of the Center
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G. (2013) · Diabetes Care · doi:10.2337/dc12-2491 · Cited by 480
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341
Effects of Exercise on Cardiovascular Risk Factors in Type 2 Diabetes
Chudyk, A., & Petrella, R. J. (2011) · Diabetes Care · doi:10.2337/dc10-1881 · Cited by 331
“5% decrease in HbA1c, depending on the pharmaceutical agent used and the baseline HbA1c level of the individual (30).”
MethodThe Effect of Oral Antidiabetic Agents on A1C Levels
Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J. E., & Gerstein, H. C. (2010) · Diabetes Care · doi:10.2337/dc09-1727 · Cited by 317
Wilding, J. P. H., Charpentier, G., Hollander, P., González‐Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12322 · Cited by 317
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Bosi, E., Scavini, M., Ceriello, A., Cucinotta, D., Tiengo, A., Marino, R., Bonizzoni, E., Giorgino, F., & on behalf of the PRISMA Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0092 · Cited by 105
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L. (2010) · Diabetes Care · doi:10.2337/dc09-2334 · Cited by 78
Grimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63
Yang, H. K., Lee, S.-H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., Rhee, E. J., Min, K. W., & Yoon, K.-H. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0054 · Cited by 25
van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06137-0 · Cited by 25
Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14000 · Cited by 21
Metadata
- Authors
- Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-09-01
- Volume
- 29
- Issue
- 9
- Pages
- 2137-2139
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2042129134
- Cited by
- 219
- References
- 0
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.